corporal aspiration
corpora injection with an α-adrenergic agent
corpora injection with an α-adrenergic blocker
no treatment required
B. corpora injection with an α-adrenergic agent
increased intravesical pressure
increased detrusor pressure
increase collagen deposition in the detrusor
detrusor smooth muscle hypertrophy
PVP
HoLEP
HoLRP
TUMT
the glandular component of the prostate
the IPSS questionnaire points
the PVR
the transitional zone volume
the aim is to occlude the internal iliac vessels
there is a considerable radiation risk during the procedure
bilateral embolization provides better results
eye protection is not required
cetrorelix
flutamide
dutasteride
zanoterone
alfuzosin
silodosin
finasteride
tamsulosin
total and free PSA
renal ultrasonography
creatinine clearance
uroflowmetry
the most potent androgenic hormones in BPH development is DHT
type-2 steroid 5 α-reductase, is most commonly found in the prostate
castrated individuals before puberty will not develop BPH
as a man ages, the number of androgen receptors in the prostate decreases
complicates approximately 0.7% of cataract surgery cases
manifests as poor preoperative pupil dilation, iris prolapse, and progressive intraoperative miosis
it could persist long after the discontinuation of tamsulosin
intraoperative lidocaine reduces its incidence in patients taking α- adrenergic inhibitors
bladder neck
apex
median lobe
para-collecular
operation time
duration of in-hospital stay
amount of blood transfused
time to catheter removal
the size of the prostate correlates well to the degree of obstruction
a decrease of 3 points in IPSS is associated with a subjective perception of improvement
median lobe enlargement gives rise to serious obstructive symptoms
bladder trabeculation is not specific for an obstructing prostate
tuberculous prostatitis
prostatic cancer
inspissated prostatic abscess
any of the above
prostatic infarction
prostate infection
bladder overdistention
all of the above
obstruction results in bladder smooth muscle hypertrophy and myofibroblasts deposition
BPH occurs chiefly in the transitional zone and periurethral tissues
BPH microscopical changes begin in early thirties
histologic findings of chronic prostatitis are common in BPH
men with storage symptoms
men with ED
failed combination of α-adrenergic blocker and 5α-reductase inhibitor
a & b
renal insufficiency
urinary retention
dry mouth
painless hematuria
occurs because of absorption of non-sodium-containing irrigating fluid
occurs only on using unipolar TURP
results in brain edema due to dilutional hyponatremia
positioning the patient in anti-Trendelenburg helps prevent the syndrome
enoxaparin
silodosin
finasteride
tolterodine
α1-a
α1-b
α2-a
α2-b
urolithiasis
receiving chemotherapy
upper tract surgery
painless hematuria
tamsulosin
alfuzosin
doxazosin
silodosin
62 - 78%
48 - 61%
79 - 93%
34 - 47%
nearly all men have PVR of less than 12 ml
it predicts the outcome of surgical treatment
it correlates well with BPH/LUTS
it is diagnostic for bladder outlet obstruction
bladder stones
BPH
prostatitis syndrome
. What is (are) the indication(s) of antimuscarinic agents and PDEIs
is specific for prostate symptom
is a seven-question, self-administered questionnaire that yields a total score that ranges from 0 to 35
a sum of 20 on IPSS scale is severe
it covers both voiding and storage symptomatology
symptoms begin with a serum sodium of less than 120 mEq/L
the mortality is 2.7-5.8 %
manifestations rely on acute changes in the intravascular volume and plasma solute concentrations
the preferred height of irrigating fluid is 60 cm above the patient
TURP
TUIP
HoLEP
HoLRP
milder postoperative hematuria
tension-free bladder closure
extra-peritoneal approach
. When comparing TURP to open prostatectomy for removing prostatic adenoma, the latter has the following advantages, EXCEPT:
operating on patients with multiple bladder diverticula
operating on patients who cannot flex their hips and/or knees
unfavorable tissue preservation for pathological examination
. What is (are) the contraindication(s) to open prostatectomy for prostatic adenoma?